CM
PTGX icon

Caption Management’s Protagonist Therapeutics PTGX Stock Holding History

Caption Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.4M Buy
150,000
+25,200
+20% +$2.63M 0.09% 250
2026
Q1 		$13.2M Sell
124,800
-50,000
-29% -$4.43M 0.08% 276
2025
Q4 		$15.3M Buy
174,800
+156,800
+871% +$12.8M 0.1% 234
2025
Q3 		$1.2M Sell
18,000
-117,000
-87% -$6.65M 0.01% 1044
2025
Q2 		$7.46M Sell
135,000
-153,600
-53% -$7.37M 0.08% 287
2025
Q1 		$14M Buy
+288,600
New +$12.1M 0.13% 137
2023
Q3 		– Sell
-290,500
Closed -$8.02M – 1493
2023
Q2 		$8.02M Buy
290,500
+265,500
+1,062% +$6.64M 0.14% 177
2023
Q1 		$575K Buy
+25,000
New +$420K 0.01% 760
2022
Q3 		– Sell
-548,700
Closed -$4.34M – 1781
2022
Q2 		$4.34M Sell
548,700
-47,300
-8% -$572K 0.06% 404
2022
Q1 		$14.1M Buy
596,000
+579,100
+3,427% +$16.3M 0.17% 140
2021
Q4 		$577K Sell
16,900
-220,600
-93% -$6.97M 0.01% 1216
2021
Q3 		$4.21M Buy
+237,500
New +$10.1M 0.05% 523

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Caption Management's PTGX Position: Q2 2026 in Review

Caption Management opened a new position in Protagonist Therapeutics (PTGX) in Q2 2026: 45,000 shares worth $5.52M. The stake represents 0.03% of the portfolio and ranks #554 among its holdings. This is a return to the name: Caption Management previously reported a position in PTGX as recently as Q4 2024.

Caption Management first reported a position in PTGX in Q3 2021 and has held it in 11 quarters since. The position peaked at $6.59M in Q4 2021. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Caption Management held 45,000 shares of Protagonist Therapeutics worth $5.52M as of Q2 2026.
  • Protagonist Therapeutics was a new Caption Management position in Q2 2026.
  • Protagonist Therapeutics made up 0.03% of Caption Management's portfolio in Q2 2026, its #554 holding.
  • Caption Management first reported a position in Protagonist Therapeutics in Q3 2021 and has held it in 11 quarters since.
  • Caption Management's Protagonist Therapeutics position peaked at $6.59M in Q4 2021.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Caption Management's 13F filing for Q2 2026, filed 14 Aug 2026.